Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS:

* Histologically confirmed low-grade, follicular B-cell, or mantle cell non-Hodgkin's lymphoma

  * Bone marrow biopsy required for pretreatment evaluation

    * Unilateral bone marrow biopsy allowed
    * Core biopsies allowed if they contain adequate tissue for primary diagnosis and immunophenotyping
* Relapsed or refractory disease as defined by disease progression after initial complete response (CR) or failure to achieve CR
* No bone marrow involvement ≥ 25% within the past 30 days
* No pleural effusion or significant ascites
* No active CNS involvement

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Life expectancy ≥ 3 months
* Platelet count ≥ 100,000/mm\^3
* Absolute neutrophil count ≥ 1,500/mm\^3
* AST ≤ 2.5 times upper limit of normal (ULN)
* Total bilirubin ≤ 2.5 times ULN
* Creatinine clearance ≥ 50 mL/min
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* Hepatitis B surface antigen negative
* No current infection with hepatitis B virus
* No HIV positivity
* No neuropathy or neuropathic pain ≥ grade 2
* No history of allergic reaction to boron or mannitol
* No active serious infection or medical or psychiatric illness that would preclude study therapy
* No other malignancy within the past 5 years except for the following:

  * Basal cell or squamous cell carcinoma of the skin that has been completely resected
  * In situ malignancy that has been completely resected
  * T1-T2a, N0, M0 prostate cancer treated with a prostatectomy or radiotherapy within the past 2 years with an undetectable PSA level
* No other condition, including any of the following:

  * Myocardial infarction within the past 6 months
  * New York Heart Association class III-IV heart failure
  * Uncontrolled angina
  * Severe uncontrolled ventricular arrhythmias
  * Electrocardiographic evidence of acute ischemia or active conduction system abnormalities

PRIOR CONCURRENT THERAPY:

* Recovered from all prior therapy
* More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), radiotherapy, or surgical resection of malignancy

  * No limitations on the number of prior therapies
* More than 4 weeks since prior major surgery
* More than 14 days since prior filgrastim (G-CSF) or sargramostim (GM-CSF)
* More than 14 days since prior and no other concurrent investigational agents

  * Concurrent participation in a nontreatment study allowed
* No prior radioimmunotherapy